Calamos Advisors LLC Sells 1,237 Shares of McKesson Corporation $MCK

Calamos Advisors LLC decreased its holdings in shares of McKesson Corporation (NYSE:MCK - Free Report) by 3.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,545 shares of the company's stock after selling 1,237 shares during the period. Calamos Advisors LLC's holdings in McKesson were worth $25,056,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of MCK. SurgoCap Partners LP raised its position in McKesson by 68.7% during the 3rd quarter. SurgoCap Partners LP now owns 452,261 shares of the company's stock valued at $349,390,000 after purchasing an additional 184,106 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in McKesson by 73.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 432,578 shares of the company's stock valued at $354,839,000 after purchasing an additional 183,590 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in McKesson during the 3rd quarter valued at approximately $135,352,000. Danske Bank A S bought a new position in McKesson during the 3rd quarter valued at approximately $127,487,000. Finally, Wellington Management Group LLP raised its position in McKesson by 32.9% during the 3rd quarter. Wellington Management Group LLP now owns 618,984 shares of the company's stock valued at $478,190,000 after purchasing an additional 153,182 shares during the last quarter. Institutional investors own 85.07% of the company's stock.

McKesson Stock Performance

Shares of NYSE:MCK opened at $828.27 on Friday. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00. The firm has a market capitalization of $101.45 billion, a P/E ratio of 23.82, a P/E/G ratio of 1.21 and a beta of 0.42. The stock has a 50 day moving average price of $904.11 and a 200-day moving average price of $857.26.

McKesson (NYSE:MCK - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same quarter in the prior year, the company earned $8.03 EPS. The business's revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities analysts forecast that McKesson Corporation will post 39.02 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be paid a $0.82 dividend. The ex-dividend date is Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson's dividend payout ratio is presently 9.43%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on MCK shares. Leerink Partners reaffirmed an "outperform" rating and set a $1,085.00 price target on shares of McKesson in a research report on Thursday, March 5th. Bank of America lowered their price target on McKesson from $1,040.00 to $1,000.00 and set a "buy" rating for the company in a research report on Monday, April 6th. Mizuho upped their price target on McKesson from $880.00 to $885.00 and gave the company a "neutral" rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. increased their target price on McKesson from $983.00 to $1,107.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Finally, Wall Street Zen lowered McKesson from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $972.27.

Insider Buying and Selling

In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the company's stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Maria Martinez sold 349 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the sale, the director owned 301 shares in the company, valued at $282,900.87. The trade was a 53.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,592 shares of company stock worth $3,518,555. 0.08% of the stock is currently owned by corporate insiders.

McKesson Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.